BerGenBio

Report Publication Announcement • May 16, 2017

BerGenBio ASA: First Quarter 2017 Results Presentation and Webcast

BerGenBio ASA: First Quarter 2017 Results Presentation and Webcast

Bergen, Norway, 16 May 2017: BerGenBio ASA, a clinical-stage biopharmaceutical

company developing novel, selective Axl kinase inhibitors for multiple cancer

indications, will announce its results for the first quarter 2017 on Tuesday, 23

May 2017.

A presentation by BerGenBio's senior management team will take place at 10:00 am

CET at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: Tjuvholmen

The presentation will webcast live and the link will be available at

www.bergenbio.com in the section Investors/Reports and presentations/Webcasts. A

recording will be available shortly after the webcast has finished.

The results report and the presentation will be available at www.bergenbio.com

in the section: Investors/Reports and presentations from 7:00 am CET the same

day.

-Ends-

About BerGenBio

BerGenBio (Bergen, Norway) is a clinical-stage biopharmaceutical company focused

on developing a pipeline of first-in-class Axl kinase inhibitors to treat

multiple cancer indications. The Company is a world leader in understanding the

central role of Axl kinase in promoting cancer spread, immune evasion and drug

resistance in multiple aggressive hematological and solid cancers.

BerGenBio's lead product, BGB324 is a selective, potent and orally bio-available

small molecule Axl inhibitor in Phase II clinical development in four major

cancer indications. It is the only selective Axl inhibitor in clinical

development. BGB324 is being developed by BerGenBio as a single agent therapy in

acute myeloid leukaemia (AML)/myeloid dysplastic syndrome (MDS) and in

combination with TARCEVA® (erlotinib) in advanced non-small-cell lung cancer

(NSCLC); and in combination with KEYTRUDA® (pembrolizumab) in advanced NSCLC and

triple negative breast cancer (TNBC) in collaboration with Merck & Co. Inc.

(MSD).

The Company is also developing a diversified pre-clinical pipeline of selective

Axl inhibitors including BGB149, anti-Axl monoclonal antibody.

For further information, please visit: www.bergenbio.com

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary

of Merck & Co., Inc.

TARCEVA® is a registered trademark of OSI Pharmaceuticals, LLC. and marketed by

Roche / Genentech Corp.

Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

David Dible, Mark Swallow, Marine Perrier

Citigate Dewe Rogerson

bergenbio@citigatedr.co.uk

+44 207 638 9571

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.